Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 10Melanoma 8Lung Neoplasms 8Neoplasms 7Carcinoma 6Skin Neoplasms 5Neoplasm Metastasis 5Carcinoma, Squamous Cell 5Carcinoma, Basal Cell 5Adenocarcinoma 5Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Sarcoma 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Hemangiosarcoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Adrenocortical Carcinoma 2

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × cemiplimab × Clear all
NCT05574101 2026-05-15

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
34 enrolled
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT07387198 2026-04-17

NeoMatryx

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Not yet recruiting
135 enrolled
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06981325 2026-03-11

CEMI-first

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting
34 enrolled
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
151 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT04315701 2025-11-20

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

University of Southern California

Phase 2 Active not recruiting
35 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡